Literature DB >> 22208481

Test verification and validation for molecular diagnostic assays.

Kevin C Halling1, Iris Schrijver, Diane L Persons.   

Abstract

With our ever-increasing understanding of the molecular basis of disease, clinical laboratories are implementing a variety of molecular diagnostic tests to aid in the diagnosis of hereditary disorders, detection and monitoring of cancer, determination of prognosis and guidance for cancer therapy, and detection and monitoring of infectious diseases. Before introducing any new test into the clinical laboratory, the performance characteristics of the assay must be "verified," if it is a US Food and Drug Administration (FDA)-approved or FDA-cleared test, or "validated," if it is a laboratory-developed test. Although guidelines exist for how validation and verification studies may be addressed for molecular assays, the specific details of the approach used by individual laboratories is rarely published. Many laboratories, especially those introducing new types of molecular assays, would welcome additional guidance, especially in the form of specific examples, on the process of preparing a new molecular assay for clinical use.

Entities:  

Mesh:

Year:  2012        PMID: 22208481     DOI: 10.5858/arpa.2011-0212-ED

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

Review 1.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  J Mol Diagn       Date:  2017-02-06       Impact factor: 5.568

2.  Molecular Biomarkers for the Evaluation of Colorectal Cancer.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  Am J Clin Pathol       Date:  2017-02-03       Impact factor: 2.493

3.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

4.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

5.  National Maintenance Cost for Precision Diagnostics Under the Verifying Accurate Leading-Edge In Vitro Clinical Test Development (VALID) Act of 2020.

Authors:  Richard Huang; Laura Lasiter; Adam Bard; Bruce Quinn; Christina Young; Roberto Salgado; Jeff Allen; Jochen K Lennerz
Journal:  JCO Oncol Pract       Date:  2021-04-21

6.  A Balanced Look at the Implications of Genomic (and Other "Omics") Testing for Disease Diagnosis and Clinical Care.

Authors:  Scott D Boyd; Stephen J Galli; Iris Schrijver; James L Zehnder; Euan A Ashley; Jason D Merker
Journal:  Genes (Basel)       Date:  2014-09-01       Impact factor: 4.096

Review 7.  Critical evaluation of FDA-approved respiratory multiplex assays for public health surveillance.

Authors:  John D Diaz-Decaro; Nicole M Green; Hilary A Godwin
Journal:  Expert Rev Mol Diagn       Date:  2018-06-19       Impact factor: 5.225

8.  A Regulatory Science Initiative to Harmonize and Standardize Digital Pathology and Machine Learning Processes to Speed up Clinical Innovation to Patients.

Authors:  Hetal Desai Marble; Richard Huang; Sarah Nixon Dudgeon; Amanda Lowe; Markus D Herrmann; Scott Blakely; Matthew O Leavitt; Mike Isaacs; Matthew G Hanna; Ashish Sharma; Jithesh Veetil; Pamela Goldberg; Joachim H Schmid; Laura Lasiter; Brandon D Gallas; Esther Abels; Jochen K Lennerz
Journal:  J Pathol Inform       Date:  2020-08-06

Review 9.  On the Slow Diffusion of Point-of-Care Systems in Therapeutic Drug Monitoring.

Authors:  Barbara Sanavio; Silke Krol
Journal:  Front Bioeng Biotechnol       Date:  2015-02-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.